Latest Conference Articles

An Italian team presented its research on the topic at the 2017 International Congress of Parkinson’s Disease & Movement Disorders Conference.

Anthony Lang, MD, FRCPC, professor and director of the Division of Neurology at the University of Toronto, discusses the potentially comprehensive care of investigational disease modifying treatment PRX002,

The study gauged elderly Parkinson's patients over a 5-year span.

Psychosis and dementia are major risk factors for Parkinson's patients.

Laxman Bahroo, DO, explains how no treatment has shown more efficacy for Tardive Dyskinesia against placebo than valbenazine (Ingrezza), and how its approval changes the scope of the movement disorder.

An expert offers insights on levodopa-induced motor complications in Parkinson’s disease.

Norika Malhado-Chang, MD, assistant professor of Neurology at University of California at Davis, discusses how progress in Parkinson's disease and movement disorders is changing the scope of comprehensive care, addressing non-motor symptoms, and supplying tools for the next generation of neurology specialists.

A study has found an alternative motor treatment from levodopa.

The first step in successfully treating chorea is making the correct diagnosis.

Specific dystonia cases require specific treatments.

Researchers were able to pull 25,000 hours of monitoring data.

"We have some major changes in the way we treat Parkinson's."

Associations between race/ethnicity and lack of in healthcare access were found.

John Dirk Nieland, PhD, associate professor in the Department of Health Science and Technology at Aalborg University in Denmark, discusses his research team's connection between MS and lipid metabolism, the importance of condition-inflicted models, and the encompassing nature of treating MS.

At AAPA 2017 in Las Vegas, Jennifer Carlquist PA-C, ER, CAQ said that she believed clinicians are trained in medicine to think heart disease is "an old person's disease," so they don't have it on their radar for the young people (teen years through mid-30s).

The conclusion to our 2-part interview with a leading expert in neurocognitive disorders in the geriatric patient.

Leading expert on neurocognitive disorders explains their impact on the elderly patient in this interview.

Dr. Kiki Chang sits down with MD Magazine and talks about the latest data on lurasidone.

Clyde Markowitz, MD, discusses how ocrelizumab, the most recent FDA-approved multiple sclerosis (MS) treatment, doesn't need to have "blockbuster" results to progress the state of MS treatment.

Leading eating disorder expert concludes her in-depth interview with MD Magazine by talking about some new treatments in development for these life-altering disorders.

Leading eating disorder expert Evelyn Attia, MD, sat down with MD Mag at the American Psychiatric Association meeting to talk about the correlation between obesity and eating disorders.

A leading expert on eating disorders sits down with MD Magazine at the Annual Meeting of the American Psychiatric Association meeting.

"We shouldn't reject these hypotheses, we should seek more data on them.

He and a Danish team believe they've found the cause of multiple sclerosis.

Brenda Banwell, MD, FAAP, FRCPC, Children's Hospital of Philadelphia's Neurology Division chief, talks about the cruciality of early diagnosing in pediatric multiple sclerosis patients, and how their best outcome is just being able to live a normal, everyday life.

Brenda Banwell, MD, FAAP, FRCPC, chief of Childrens Hospital of Philadelphia's Division of Neurology, speaks on new discoveries of pediatric MS at the annual 2017 Consortium of Multiple Sclerosis Centers (CMSC) in New Orleans.

The multi-dosage longterm studies of Cladribine Tablets were shared at CMSC.

The study was a continuation of a 2-year alemtuzumab study versus interferon.

The director of experimental therapeutics at the Mellen MS Center at the Cleveland Clinic shared what's shaping the soon-to-be-released update on the most recent 2010 diagnosing criteria at the 2017 Consortium of Multiple Sclerosis Centers.

Simvastatin may reduce inflammation, fibrosis, bronchial constriction, mucus